Compare Marathon Petroleum Corp (MPC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs TG Therapeutics Inc — how do they compare? Marathon Petroleum Corp trades at $461.98 (market cap $130.12B), while TG Therapeutics Inc trades at $55.27 (market cap $8.16B). The key difference: Marathon Petroleum Corp is far larger — about 15.9× TG Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and TG Therapeutics Inc for 15 Days on average.
| MPC | TGTX | |
|---|---|---|
Market Cap | $130.12B | $8.16B |
Volume | 2,749,647 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $463.34 | $59.06 |
52-Week Low | $162.63 | $26.94 |
Typical Hold Time | 54 Days | 15 Days |
Enterprise Value | $156.64B | $8.37B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $461.79, up 4.42% today, showing strong momentum with three consecutive earnings beats. Technical indicators signal bullish momentum with the stock trading near resistance at $463. Fundamentally, the company maintains solid profitability with 5.57% net margin and 47.9% ROE, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Analyst consensus remains strongly bullish with 25 buy ratings and a $420.30 price target.
MPC presents a compelling value opportunity with attractive valuation multiples (P/E 16.07, P/S 0.9) and strong earnings momentum. Key risks include potential diesel export restrictions, declining revenue trends, and elevated debt levels. The stock's current price above consensus target suggests near-term caution despite positive technical and fundamental momentum.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
